1. Home
  2. IMNM vs DCBO Comparison

IMNM vs DCBO Comparison

Compare IMNM & DCBO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMNM
  • DCBO
  • Stock Information
  • Founded
  • IMNM 2006
  • DCBO 2016
  • Country
  • IMNM United States
  • DCBO Canada
  • Employees
  • IMNM N/A
  • DCBO N/A
  • Industry
  • IMNM Medicinal Chemicals and Botanical Products
  • DCBO
  • Sector
  • IMNM Health Care
  • DCBO
  • Exchange
  • IMNM Nasdaq
  • DCBO Nasdaq
  • Market Cap
  • IMNM 945.8M
  • DCBO 893.7M
  • IPO Year
  • IMNM 2020
  • DCBO 2020
  • Fundamental
  • Price
  • IMNM $9.01
  • DCBO $30.15
  • Analyst Decision
  • IMNM Strong Buy
  • DCBO Strong Buy
  • Analyst Count
  • IMNM 8
  • DCBO 5
  • Target Price
  • IMNM $24.75
  • DCBO $42.20
  • AVG Volume (30 Days)
  • IMNM 1.0M
  • DCBO 84.3K
  • Earning Date
  • IMNM 11-12-2025
  • DCBO 11-07-2025
  • Dividend Yield
  • IMNM N/A
  • DCBO N/A
  • EPS Growth
  • IMNM N/A
  • DCBO 33.51
  • EPS
  • IMNM N/A
  • DCBO 0.69
  • Revenue
  • IMNM $12,589,000.00
  • DCBO $230,502,000.00
  • Revenue This Year
  • IMNM N/A
  • DCBO $13.02
  • Revenue Next Year
  • IMNM $154.73
  • DCBO $8.37
  • P/E Ratio
  • IMNM N/A
  • DCBO $43.09
  • Revenue Growth
  • IMNM 16.74
  • DCBO 15.11
  • 52 Week Low
  • IMNM $5.15
  • DCBO $25.50
  • 52 Week High
  • IMNM $16.73
  • DCBO $53.86
  • Technical
  • Relative Strength Index (RSI)
  • IMNM 43.25
  • DCBO 45.53
  • Support Level
  • IMNM $9.01
  • DCBO $29.72
  • Resistance Level
  • IMNM $9.63
  • DCBO $30.68
  • Average True Range (ATR)
  • IMNM 0.71
  • DCBO 0.78
  • MACD
  • IMNM -0.07
  • DCBO -0.15
  • Stochastic Oscillator
  • IMNM 17.38
  • DCBO 15.18

About IMNM Immunome Inc.

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.

About DCBO Docebo Inc.

Docebo Inc is a provider of cloud-based learning management systems. The solutions provided by the company allow learning administrators to deliver scalable and flexible personalized learning experiences, from formal training to social learning to multiple internal, external, and blended audiences. The group provides an easy-to-use, configurable, and affordable learning platform with the end-to-end capabilities and critical functionality needed to train both internal and external workforces, partners, and customers. The majority of the revenue is derived from customers based in North America.

Share on Social Networks: